Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-Term Follow-Up to Evaluate the Safety of LX1001 in Participants With APOE4 Homozygote Alzheimer's Disease

NCT05400330 is registered in ClinicalTrials.gov with Lexeo Therapeutics as lead sponsor.

NCT NCT05400330
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05400330 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-Term Follow-Up to Evaluate the Safety of LX1001 in Participants With APOE4 Homozygote Alzheimer's Disease
Lead sponsor
Lexeo Therapeutics
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 8, 2023
Completion date
November 30, 2028
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease